Monthly Archives: March 2021

FORT LAUDERDALE, Fla., March 16, 2021 /PRNewswire/ --Graystone Company, Inc. (OTC: GYST) announced today the completion of the formulation of one of its signature products, Fucoidan Longevity Booster, the flagship product for its Immune Support, Anti-Inflammatory & Anti-Aging Product Line.

The Fucoidan Longevity Booster represents the initial product in the expected line of products that will address immune support, anti-inflammatory and anti-aging. Independent studies(1) on fucoidan suggest that it can prevent the growth of cancer cells and has antiviral, neuroprotective, and immune-modulating effects.Additionally, published papers(2) have reported that fucoidan mayexert a range of beneficial effects on the human immune system, including the reduction of allergic responses and the activation of dendritic cells, natural killer cells and T cells. It has also been shown that fucoidan has the potential to boost important anti-viral, anti-tumor and anti-aging responses.

Traditional Fucoidan powder found in many products offered today, due to its molecular weight is normally only absorbed in the intestine, whereas benefits are delayed by the normal digestive process. Graystone has been committed to delivering the only capsulized nano-formulation that will improve the absorption and effectiveness of the Fucoidan.

Market research indicate that the wellness supplement market is expected to grow to $386.29 billion by 2027.(3) This ever-growing trend towards healthy lifestyles is a positive for Graystone for the foreseeable future.

(1)https://www.mskcc.org/cancer-care/integrative-medicine/herbs/fucoidan

(2)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6780838/

(3)https://www.databridgemarketresearch.com/reports/global-wellness-supplements-market

About The Graystone Company, Inc.Graystone Company develops Wellness, Longevity and Anti-Aging products. The Graystone Company, Inc. (OTC PINK:GYST)is headquartered in Fort Lauderdale, FL., and can be reached at http://www.thegraystonecompany.com or by phone at (954) 271-2704.

Notice Regarding Forward-Looking Statementsin this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Actual results could differ from those projected in any forward-looking statements due to numerous factors. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate.

For more information:

Graystone Company

Email: [emailprotected]

Phone: (954) 271-2704

SOURCE Graystone Company, Inc.

Visit link:
Graystone Company Completes Formulation of its Nano-Delivery of the Fucoidan Longevity Booster - PRNewswire

As a local general practitioner, I wish to support the sentiment expressed by Sue Saw in last weeks letter section (Question all levels of government on pandemic, Pique, March 11).

For the past 12 months I too have been profoundly disturbed by the medias role in creating and maintaining a constant state of hypervigilance regarding COVID-19.

Measured in terms of threat to quality human life years, coronavirus would not make the top 10 on my personal list of preventable or modifiable risks to human health and longevity. In fact, I have yet to lose a single patient to the disease.

But I do worry about how many clients I may ultimately lose due to this irrational overreaction to the disease, akin to an auto-immune response, bordering on anaphylaxis.

The media has done a brilliant job of documenting the daily death toll related to COVID-19, but the vast collateral damage of the drastic measures imposed to limit its spread will likely never be tabulated.

For most members of the population, conditions such as hypertension, diabetes, coronary artery disease and cancer are all greater threats than is the current virus in circulation. Yet panic over the possibility of contracting infection has led to serious delays in diagnosing and managing these conditions for many individuals.

In the elderly, social integration has long been recognized as vital to maintaining mental and physical health, and yet they have been denied this basic right for over a year.

At any demographic level, anywhere in the world, the economic downturn due to political responses to the pandemic is causing and aggravating poverty, another factor intimately linked to poor health and premature death.

Fear of the virus has also discouraged ridership on public transport, even though it is 100 times safer than personal motor transportation, in terms of risk of accidental injury or death. I would guess that the average age of the pandemics collateral victims is well under that of the average age of those who have succumbed to the infection, magnifying the ultimate tally of unnecessary life-years lost.

Like all other living things, human beings have always been dying of infectious disease. History is a litany of waves of epidemics and pandemics, most far more deadly than the current one. I find it extraordinary and hypocritical that we suddenly have become so risk-adverse to a virus while we continue to blissfully play Russian roulette with so many fundamental life-sustaining elements of our biosphere, including climate stability.

Depending on the evolution of coronavirus strains, herd immunity and vaccination programs may ultimatelyprovide at least temporary reprieve from propagation of the disease itself, but what I would really like to see is development of a vaccine versus paranoia and mass hysteria, to help us achieve herd immunity to brainwashing by fear-mongeringpoliticians and members of the media.

Thomas DeMarco MD // Whistler

The rest is here:
LETTER TO THE EDITOR: We need herd immunity against brainwashing politicians - Pique Newsmagazine

It may sound like science fiction, but there was a time when people were optimistic about the future. Perhaps no other decade embodies that optimism than the 1960s, though maybe it was all of the psychedelic drugs. Still, we made it to the moon, and sci-fi shows like Star Trek offered an inspiring vision of exploring strange new worlds and exotic alien bodies. The same year Capt. Kirk beamed across the galaxy, a movie called Fantastic Voyage hit the big screen in 1966. The film was about a submarine crew who are shrunk to microscopic size in order to enter the body of an injured scientist to repair damage to his brain. Crazy, impossible stuff, right?

Fifty-something years later, psychedelics are an emerging therapy, were headed back to the moon to mine for riches, and William Capt. Kirk Shatner has released eight spoken-word albums but has yet to win a Grammy. And, oh, were about to send miniature robots into the human body to help repair damage to the brain and the rest of the central nervous system. Lets meet the startup on this fantastical journey.

Founded in 2016, Los Angeles-based Bionaut Labs came out of stealth mode this month by raising a $20 million Series A led by one of the top tech-loving venture capital (VC) firms, Khosla Ventures, which also participated in an undisclosed Seed round a couple of years earlier. Another investor is BOLD Capital, a VC outfit where Peter Diamandis serves as general partner. The well-known billionaire futurist invests in what he calls exponential technologies, particularly in areas like human longevity.

In a blog post about the value proposition of the company, Diamandis wrote:

Technologies such as Bionauts and the many other medical robots entering the healthcare arena are resulting from the extraordinary convergence of exponential technologies. The combination of computation, AI, sensors, networks, 3D printing, VR and AR is transforming how we find and treat disease.

Another thing to note before we talk about what has Diamandis so excited about Bionaut Labs is that several members of the startups leadership and advisory board have affiliations with a company called PrimeSense. Never heard of it? Us neither, but most of us are familiar with Microsofts Xbox. Microsoft (MSFT) acquired PrimeSense, which had developed 3D motion-sensing technology used in the Xbox 360, for $360 million in 2013. One PrimeSense alumnus is Michael Shpigelmacher, co-founder and CEO of Bionaut Labs, who has also done stints at McKinsey & Company and hedge fund company PDT Partners that was spun off from Morgan Stanley about a decade ago. So this is a company, as they say, with proven leadership.

In a nutshell, Bionaut Labs is developing remote-controlled robots smaller than a grain of rice that navigate through the body for precision treatment of disease, starting with the brain and central nervous system. We need to make a quick distinction here: Precision medicine, also known as personal medicine, applies genetics, machine learning, and other tools in order to tailor treatments as much as possible to a persons particular physiology. Thats different from what Bionaut Labs is doing, which is creating a precise drug delivery platform, rather than the spray-and-pray approach of most medical therapies today. This is also different from the robotic pills that weve written about before that are designed to replace injections.

Measuring less than one millimeter in length, the 3D-printed Bionauts contain moving parts controlled remotely by a magnetic guidance system. The magnetic energy required to operate the robot is less than 10% of that used in MRIs and is much cheaper to generate, according to Diamandis. These miniature medical machines are actually capable of autonomous operation but humans will remain in the loop, especially in the early days.

The bot is injected either into the lumbar spine, like in an epidural procedure, or behind the skull. It then speeds and slices its way through tissue to the target site, such as a tumor, where it is magnetically triggered to release a drug payload from the cargo compartment. The robot then returns the way it came. Bionauts can even go off road compared to conventional technologies that stick to established routes such as the vasculature. For example, they can swim through cerebrospinal fluid or even burrow through brain tissue. The accuracy is on par with surgeons, with a deviation of just one millimeter. The robot can be designed in a range of sizes, payloads, shapes, topologies, functions, and flavors. We might have made up one of those.

Bionaut Labs claims that roughly half of all approved medicines treat diseases that are local in nature, where precision targeting using its wee robots offers better results and less chance of side effects. The company is initially targeting its robotic drug delivery system against glioma and Huntingtons disease. The former is a type of tumor that forms in the brain or spine, representing 80% of all malignant brain tumors. The latter is a progressive degenerative brain disease with few treatment options.

Eventually, the company believes its robots could become diagnostic tools in addition to therapeutic ones by remaining in the body to detect disease before symptoms occur. Diamandis predicts even more futuristic versions, such as even smaller Bionauts for minimally invasive treatments of eye disease.

Thats all still well into the future. The company is currently in the preclinical phase, testing the Bionauts on pigs and sheep, with human clinical trials still a couple of years away.

We started Nanalyze nearly 20 years ago over our sheer fascination with the potential of nanotechnology. The idea that microscopic machines nanobots as we used to call them could someday help treat disease was one of the most exciting applications of the technology. Its already happening in areas like synthetic biology, which is engineering biological machines out of bacteria, proteins, and more. While not yet on the nanoscale, Bionauts represent the first generation of miniature mechanistic machines that can do a big job.

Pure-play disruptive tech stocks are not only hard to find, but investing in them is risky business. That's whywe created The Nanalyze Disruptive Tech Portfolio Report. Find out which tech stocks we love, like, and avoid in this special report, now available for all Nanalyze Premiumannual subscribers.

Continue reading here:
Bionaut Sends Robots into the Human Body to Treat Disease - Nanalyze

The days of cream and sugar are over. There's a new ingredient in town that everyone is putting in their coffeeand it's not just for flavor: adaptogens.

"Adaptogens are nontoxic herbal pharmaceuticals which claim to help us better cope with (or increase our resistance to) mental or physical stress, improving physical and mental performance, and possibly supporting the immune system," says Silvia Carli, MS, RD, registered dietitian for 1AND1 LIFE. (Related: 11 Healthy Foods That Make You Smarter, According to Doctors.)

Many of the new canned and bottled coffee drinks use adaptogens to help deliver all the focus of caffeinated coffee but with less of a crash or jitters while providing stress-relieving benefits.

While adaptogens have been used for thousands of years in traditional herbal medicine, they're only recently becoming more commonplace as more research is being done to confirm their benefits.

"Functional mushrooms are finally having their moment in the public spotlight, in large part due to the growing amount of research into their health benefits as well as their applications in food," says Kerry Hughes, MS, CNC, a certified clinical nutritionist, ethnobotanist and herbalist who is on the Scientific Advisory Board for Good Pharma.

If you've ever felt too jittery after drinking plain coffee, you might be interested in drinking adaptogen-enriched coffee, which is often much lower in caffeine than a traditional cup of joe while also having the benefits of functional mushrooms.

As adaptogens have been linked to lower stress levels, adding them to coffee may help to lower our level of stress and burnout in an easy wayby adding it to something we drink every day anyway.

"The search is on for more natural and accessible ways to manage stress that may also have additional health benefits such as increased cognitive function as well as boost immunity," says Aimee Plauche, RD, an advising registered dietitian for ICONIC. And adaptogens are one of the ways to do this.

These mushrooms and roots have been used in Chinese and Ayurvedic medicine for thousands of years, but we're just starting to do more research into adaptogens to prove their benefits.

"While more research is needed, studies on the utility of certain adaptogens seem promising," saysKylie Ivanir, MS, RD, a registered dietitian atWithin Nutrition.

"Studies conducted in animals and in human cell samples have shown that adaptogens may indeed demonstrate neuroprotective activity, have anti-fatigue and antidepressant properties, and can serve as a stimulant for the central nervous system. Studies have shown that particular adaptogens, such as Rhodiola extract, can improve cognitive function and combat fatigue," says Ivanir.

She adds that larger research studies completed on humans are needed to determine the efficacy of each particular adaptogen.

There are a few common adaptogens that are used more frequently in coffee:

Adaptogen coffee has some great added benefits, but experts say you shouldn't be drinking it as a solution to your underlying health problems.

"It's not that adaptogens would not improve your quality of life if you are extremely stressed, but is that the factor that is going to make the biggest difference?" says Carli.

She recommends taking a closer look at your daily habits: "I want to invite the readers to reflect on a couple of points: are there other adjustments that we can make in our daily routine to ease the stress in our lives? For example: are we practicing self-care, eating an overall healthy, varied, and balanced diet without overly processed foods? Are we sleeping well? Do you journal? Do you exercise? Do you have an outlet to talk about your stressors?" says Carli.

If you're dealing with a lot of stress, it might be best to combine your adaptogen coffee with other stress-reducing habits.

Adaptogens aren't for everyone. And it's not just about personal preferencetaking adaptogens isn't safe for certain people.

"It is important to note that certain adaptogens may not be safe for everyone including pregnant women, so it is always best to consult with your healthcare provider," says Ivanir.

As with any supplement, Carli notes that you should make sure the adaptogens you're consuming are safeespecially considering that these are a fairly new product.

"When new supplements get on the market quickly due to new trends (sometimes poorly supported by research), the process of testing for quality and purity is not always ideal and thorough, which means that we are not certain of the actual contents of that supplement and it could turn out being harmful to health," says Carli. (Related: 6 Popular Supplements That Don't Actually Work, According to Experts.)

That's why Ivanir tells that it's important to choose reputable brands that have been third-party tested to ensure there are no contaminants or heavy metals.

And although the benefits of adaptogens sound enticing, it's always good to keep in mind that it's best to not rely on taking these ingredients alone for their benefits without following a well-balanced diet.

"Adaptogens should not take the place of a balanced diet, physical activity, and any necessary medications, they may be used as a supplement to support overall health," adds Ivanir.

So in addition to drinking adaptogen coffee, you can also try these22 Proven Tricks That Melt Stress.

For more healthy eating news, make sure to sign up for our newsletter!

Read more here:
The One Ingredient Everyone's Adding to Their Coffee | Eat This Not That - Eat This, Not That

While a person cant stop ageing, you can, in a way, slow it down. There is no easier way to do so than through healthy lifestyle habits. By consuming raw honey moderately, you could help increase your lifespan, experts say.

Honey is widely accepted as food and medicine by all generations, traditions and civilisations, both ancient and modern.

Honey is a sweet, flavourful liquid food of high nutritional value and immense health benefits.

Some of the vitamins found in honey include ascorbic acid, pantothenic acid, niacin and riboflavin; along with minerals such as calcium, copper, iron, magnesium, manganese, phosphorus, potassium and zinc.

READ MORE:Hair loss treatment: Green tea could prevent balding and support hair growth

In a study published in the National Library of Health, the effects of honey and its mechanisms of action on the development and progression of cancer was analysed.

The study noted: Honey is a natural product known for its varied biological or pharmacological activities-ranging from anti-inflammatory, antioxidant, antibacterial, antihypertensive to hypoglycaemic effects.

Effects of honey have been thoroughly investigated in certain cancers such as breast, liver and colorectal cancer cell lines. In contrast, limited but promising data are available for other forms of cancers including prostate, bladder, endometrial, kidney, skin, cervical, oral and bone cancer cells.

Honey is highly cytotoxic against tumour or cancer cells while it is non-cytotoxic to normal cells.

Thus, honey may serve as a potential and promising anticancer agent which warrants further experimental and clinical studies.

DON'T MISSDoes Pfizer vaccine cause blood clots?[INSIGHT]Alcohol-related liver disease: Three signs[TIPS]Bowel cancer: Narrow poo is a visual sign[ADVICE]

Cardiovascular diseases are the leading causes of death worldwide.

However, the use of honey may help to address each of the factors contributing to heart disease.

For one, elevated levels of poor low-density lipoprotein (LDL) cholesterol raise the risk of heart disease.

This is because it can lead to blocked arteries, which then increases the risk of heart attacks and strokes.

However, studies have found that honey not only helps to lower the levels of LDL cholesterol, but it also serves to raise the levels of good high-density lipoprotein (HDL) cholesterol.

Produced in New Zealand by bees that pollinate the Manuka tree, this form of honey is known for its rich nutritional value as it contains high levels of amino acids, B vitamins, calcium, iron, magnesium and other essential nutrients making it one of the healthiest types of honey out there.

While regular honey may contain the same nutrients, the reason as to why the Manuka one has a better reputation is because it contains additional compounds that make it even more beneficial for human health.

All kinds of honey have been used as natural antibiotics throughout the centuries. In recent years, researchers have discovered that honeys power to kill germs comes from hydrogen peroxide produced with the help of a bee enzyme.

Manuka honey takes this a step further by attacking germs with a substance called MGO. Found in the nectar of some Manuka plants, this substance helps heal both minor and chronic wounds.

Anti-ageing is about postponing the onset of old age, while maintaining strong and healthy body.

Raw Manuka honey not only protects ones overall health, it also boosts your metabolism.

Having a sluggish metabolism and slow fat burning are typical of old age.

By replacing sugar with honey, you will speed up the rate at which you burn calories and thus lose weight natural way.

Studies have also indicated that by consuming raw honey you will have better endurance when it comes to exercising.

By losing weight, reducing your risk of cancers and heart disease you can help boost your longevity.

Read the rest here:
How to live longer: Honey to help reduce cancer risks, increase memory & boost longevity - Express

March 19, 2021 @ 13:28 by Chloe Holmes

Together with VOICE, The UKs National Innovation Centre for Ageing will launch their very first citizen-led community in the US.

Through a commercial agreement, VOICE (Valuing Our Intellectual Capital & Experience) and the UKs National Innovation Centre for Ageing (NICA) have set up a partnership with a non-profit organisation called amazing.community.

Headquartered in New Jersey (US) the amazing.community supports women aged 45+ as they navigate the present and future of work in this digital world; the organisation offers cutting edge skills building opportunities, curated resources, and an open virtual door for women 45+ to connect meaningfully with each other.

This new partnership will help build a more diverse VOICE community and facilitate cultural exchanges between US and UK. NICA and amazing.community will work together to explore the impact of technology at work, ageism, gender equality, cultural differences and the many issues and challenges that need to be addressed to ensure women over 45 thrive in the workplace now and in the future.

All this is building a deep global knowledge and rich consumer insights on healthy ageing. It gives businesses, entrepreneurs, innovators, and policy makers a novel and unique source of data and insights, building the evidence base to rapidly inform the development of new products and services helping people to live well for longer and tapping into a billion-pound longevity economy.

NICA, who are based within Newcastle University, UK on Newcastle Helix, is the UK home of Ageing Intelligence, which brings together data driven insight and human experiences to help bring new products, business models and services to market. VOICE is part of NICA and leads dialogue with citizens on what is needed for healthy ageing.

VOICE currently has a citizen network of more than 8,000 people the UK and this expansion is part of NICAs strategy to provide services and insight on ageing at a global level. It is intended that this business model will be replicated in other countries around the world, building a broader repository of data and insight to empower new business opportunities and ideas.

Professor Lynne Corner, chief operating officer at NICA and director of VOICE said: This marks the first step in our global ambitions for the VOICE community and we are thrilled to partner with the wonderful team at amazing.community and support ageing innovation in the US.

This is a strategic decision to develop a more culturally and gender diverse community to generate broader, deeper, richer insights and cultural exchanges between individuals from all over the world. It will provide to clients, business and policy makers a novel and unique source of insight.

This new business model is not only commercially viable, but also a way to empower parallel communities to come together and amplify their voices sharing experiences, exchanging insights, and building on common ground. Our plans will not only support international longevity economies but make a lasting impact on peoples lives helping them live well for longer.

amazing.community will be able to take advantage of ten years of operational expertise in community engagement from the VOICE network in the UK. Branded as Amplified by VOICE, amazing.community has customized the VOICE digital platform to engage and grow their existing community as well as to invite more robust collaboration with companies, non-profits and other organisations.

Dr. Ashley Ater Kranov, executive director of amazing.community, said: Im thrilled to announce our global partnership with VOICE. It has been nearly a year in the making and we are beyond ready to bring our communities together.

This partnership forwards one of our strategic initiatives: to establish close ties with a center for aging known for applied research, community engagement, and a commitment to transforming individual lives and impacting policy. Our collaboration will allow each of our communities to participate in tech skills building opportunities, quality of life research studies and special interest group discussions offered by both organizations.We believe doubling our offerings and opening the door to an international community will meaningfully enhance our efforts to expand the work horizon for women 45+ who are looking to re-enter the workforce, pivot to a new career or start their own businesses.

To celebrate this global partnership, and to bring both communities together for an engaging cross Atlantic conversation, they will watch the exclusive premiere of the film Les Dames (Ladies).

The acclaimed Swiss film Ladies by directors Stphanie Chuat, Vronique Reymond is a movie that reveals the passions, intimacy, and desires of five women who, at the dawn of their 60s or older, dream of their future. This will be a first-world premiere and will also mark the start of a joint research piece on love, life, companionship for women in later life.

For more information or to sign up to be part of the VOICE community visit https://www.voice-global.org/about/ (UK) or https://amazing.community (US).

Here is the original post:
Global expansion for UK National Innovation Centre with a new VOICE in the US - North East Times

EDISON BIO is expanding human health potential.

HOUSTON (PRWEB) March 19, 2021

Houston health tech company EDISON BIO has launched what may be the most comprehensive executive health exam on the planet. This new physical of the future aggregates a wide array of health data to create a truly universal digitalization of patients minds and bodies focused on improving longevity and performance. EDISON BIOs Artificial Intelligence, combined with a team of medical experts, analyzes health changes at the first signs of detection long before they have the chance to progress into serious health concerns. By analyzing this personalized data, EDISON BIO can uncover potential health risks and create an educational, highly personalized health strategy focused on optimizing diet, exercise, and lifestyle to improve overall performance and longevity. This approach aims to empower people to achieve the most in-depth understanding of all areas of their health in a way never before imagined.

Despite all the advances of modern medicine, todays healthcare system still largely takes a reactionary approach, catching disease only after symptoms manifest. By that time, it is often too late to reverse the resulting damage. The team at EDISON BIO believes that no one should have to wait until their disease becomes too harmful for treatment and is accelerating access to the latest in medical detection technology.

In contrast to the routine exam and minimal blood work done by many doctors today, EDISON BIO uses the latest technology to collect extensive data including full-body MRI imaging, a full array of genomic technology including whole genome sequencing, extensive blood analysis, and diet, lifestyle, and mental health evaluations to determine current and future health risks. This scientifically quantified data empowers members with confidence and peace of mind as to the comprehensive state of their health.

EDISON BIOs founder realized the need for proactive awareness of health risks when a cancer screening technology saved his mothers life. Around the same time, a family friend passed away after cancer was detected too late. He and his team have spent nearly twenty years researching and experimenting with medical technology to make medicine more personalized and less reactionary in nature. He believes that it will change the way people engage with their health through anticipating concerns early on and empowering people with personalized tools to achieve their optimum health.

EDISON BIO conducts exams at their members preferred location, including their homes, corporate offices, or wherever they are requested. After the biomarkers are analyzed, they offer an easy-to-understand educational plan to address concerns as well as rapid access to the worlds leading experts if a rare condition or disease is detected.

EDISON BIO is using evidence-based, data-driven technology to expand human health potential. Named in homage to Thomas Edisons invention of the light bulb, EDISON BIO is illuminating the future of healthcare in the twenty-first century by providing a more personalized, preventive, and data-driven approach to health.

EDISON BIO Contact: http://www.edisonbio.com / support@edisonbio.com / Phone: 888-366-0123

Share article on social media or email:

See original here:
EDISON BIO Launches Advanced Executive Health Exam For Early Detection Of Health Risks - PR Web

New York, March 16, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Stem Cell Therapy Industry" - https://www.reportlinker.com/p06033005/?utm_source=GNW In addition to being a global intelligence exchange platform, MarketGlass is a powerful knowledge center that delivers dynamic project-focused market intelligence. Client companies will have complete insider access to the project Data stack. - Interactive peer-to-peer and enterprise-to-enterprise ideation and market intelligence exchange is facilitated via a robust, secure, and validated process. The process draws from uniquely qualified project-specific and geographically focused executives overseeing business development, marketing and sales operations.

Abstract: - Global Stem Cell Therapy Market to Reach $242.3 Million by 2027 - Amid the COVID-19 crisis, the global market for Stem Cell Therapy estimated at US$127.5 Million in the year 2020, is projected to reach a revised size of US$242.3 Million by 2027, growing at aCAGR of 9.6% over the period 2020-2027. Allogeneic, one of the segments analyzed in the report, is projected to record 9.9% CAGR and reach US$228.6 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Autologous segment is readjusted to a revised 5.6% CAGR for the next 7-year period. - The U.S. Market is Estimated at $37.8 Million, While China is Forecast to Grow at 9% CAGR - The Stem Cell Therapy market in the U.S. is estimated at US$37.8 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$41.9 Million by the year 2027 trailing a CAGR of 9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.8% and 7.8% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 7.8% CAGR.

Select Competitors (Total 33 Featured) -

Read the full report: https://www.reportlinker.com/p06033005/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW Influencer Market Insights World Market Trajectories Impact of Covid-19 and a Looming Global Recession Global Competitor Market Shares Stem Cell Therapy Competitor Market Share Scenario Worldwide: ( in %): 2020E Global Competitor Market Shares by Segment

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE Table 1: World Current & Future Analysis for Stem Cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 2: World Historic Review for Stem Cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 3: World 15-Year Perspective for Stem Cell Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027

Table 4: World Current & Future Analysis for Allogeneic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 5: World Historic Review for Allogeneic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 6: World 15-Year Perspective for Allogeneic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 7: World Current & Future Analysis for Autologous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 8: World Historic Review for Autologous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 9: World 15-Year Perspective for Autologous by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 10: World Current & Future Analysis for Gastrointestinal Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 11: World Historic Review for Gastrointestinal Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 12: World 15-Year Perspective for Gastrointestinal Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 13: World Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 14: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 15: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 16: World Current & Future Analysis for Musculoskeletal Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 17: World Historic Review for Musculoskeletal Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 18: World 15-Year Perspective for Musculoskeletal Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 19: World Current & Future Analysis for Wounds & Injuries by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 20: World Historic Review for Wounds & Injuries by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 21: World 15-Year Perspective for Wounds & Injuries by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 22: World Current & Future Analysis for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 23: World Historic Review for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 24: World 15-Year Perspective for Cardiovascular Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 25: World Current & Future Analysis for Adipose Tissue-Derived MSCs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 26: World Historic Review for Adipose Tissue-Derived MSCs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 27: World 15-Year Perspective for Adipose Tissue-Derived MSCs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 28: World Current & Future Analysis for Bone Marrow-Derived MSCs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 29: World Historic Review for Bone Marrow-Derived MSCs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 30: World 15-Year Perspective for Bone Marrow-Derived MSCs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 31: World Current & Future Analysis for Cord Blood / Embryonic Stem Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 32: World Historic Review for Cord Blood / Embryonic Stem Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 33: World 15-Year Perspective for Cord Blood / Embryonic Stem Cells by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 34: World Current & Future Analysis for Other Cell Sources by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 35: World Historic Review for Other Cell Sources by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 36: World 15-Year Perspective for Other Cell Sources by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES Market Facts & Figures Market Analytics Table 37: USA Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 38: USA Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 39: USA 15-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2012, 2020 & 2027

Table 40: USA Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 41: USA Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 42: USA 15-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2012, 2020 & 2027

Table 43: USA Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 44: USA Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 45: USA 15-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources for the Years 2012, 2020 & 2027

CANADA Table 46: Canada Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 47: Canada Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 48: Canada 15-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2012, 2020 & 2027

Table 49: Canada Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 50: Canada Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 51: Canada 15-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2012, 2020 & 2027

Table 52: Canada Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 53: Canada Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 54: Canada 15-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources for the Years 2012, 2020 & 2027

JAPAN Table 55: Japan Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 56: Japan Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 57: Japan 15-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2012, 2020 & 2027

Table 58: Japan Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 59: Japan Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 60: Japan 15-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2012, 2020 & 2027

Table 61: Japan Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 62: Japan Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 63: Japan 15-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources for the Years 2012, 2020 & 2027

CHINA Table 64: China Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 65: China Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 66: China 15-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2012, 2020 & 2027

Table 67: China Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 68: China Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 69: China 15-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2012, 2020 & 2027

Table 70: China Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 71: China Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 72: China 15-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources for the Years 2012, 2020 & 2027

EUROPE Market Facts & Figures Market Analytics Table 73: Europe Current & Future Analysis for Stem Cell Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 74: Europe Historic Review for Stem Cell Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 75: Europe 15-Year Perspective for Stem Cell Therapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027

Table 76: Europe Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 77: Europe Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 78: Europe 15-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2012, 2020 & 2027

Table 79: Europe Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 80: Europe Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 81: Europe 15-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2012, 2020 & 2027

Table 82: Europe Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 83: Europe Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 84: Europe 15-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources for the Years 2012, 2020 & 2027

FRANCE Table 85: France Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 86: France Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 87: France 15-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2012, 2020 & 2027

Table 88: France Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 89: France Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 90: France 15-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2012, 2020 & 2027

See the article here:
Global Stem Cell Therapy Market to Reach $242.3 Million by 2027 - GlobeNewswire